Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/27/26 AstraZeneca (AZN) sonesitatug vedotin for Esophageal Cancer Subscribers Only Subscribers Only Subscribers Only
7/27/26 AstraZeneca (AZN) sonesitatug vedotin for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
7/23/26 Zevra Therapeutics (ZVRA) Miplyffa for Niemann-Pick Disease Type C Subscribers Only Subscribers Only Subscribers Only
7/23/26 AstraZeneca (AZN) Etcamah for Breast Cancer Subscribers Only Subscribers Only Subscribers Only
7/23/26 AstraZeneca (AZN) Etcamah for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update